Core Viewpoint - Tongrentang is leveraging a multi-faceted strategic layout to enhance its performance in the health industry by extending its industrial chain, accelerating the transformation of scientific research results, and advancing digital transformation [1] Financial Performance - In Q1 2025, the company reported revenue of 5.276 billion yuan, a year-on-year increase of 0.16%, and a net profit attributable to shareholders of 582 million yuan, up 1.10% year-on-year [2] - The net cash flow from operating activities improved significantly from -252 million yuan in the same period last year to 833 million yuan, attributed to optimized raw material procurement and a more reasonable inventory structure [2] - Total assets reached 32.312 billion yuan, a 3.57% increase from the end of the previous year, while net assets attributable to shareholders grew by 4.38% [2] Product Development and Innovation - The company launched a new specification for the product "Angong Niuhuang Wan," focusing on both tradition and innovation to provide high-quality traditional Chinese medicine products [3] - Research efforts led to the completion of 11 quality standard studies and 4 efficacy studies on various traditional Chinese medicine products [2] Digital Transformation and Supply Chain Management - The year 2025 marks the beginning of the "Pharmaceutical Industry Digital Transformation Implementation Plan," which aims to enhance production efficiency and quality control through digital means [4] - Tongrentang is accelerating its digital transformation, focusing on supply chain management, production efficiency, and consumer services, with a commitment to transparency throughout the production and sales processes [4] - The company has implemented a traceability management system for traditional Chinese medicine, ensuring comprehensive supervision and openness across the entire industry chain [4] Technological Advancements - The upgraded Traditional Chinese Medicine Knowledge Graph System 3.0, integrated with the DeepSeek model, enhances the intelligent integration and interaction of TCM knowledge, significantly improving service capabilities [5] Policy Alignment and Long-term Growth - Tongrentang's long-term strategy aligns with national policies, particularly the ongoing "Healthy China" initiative and the revitalization of traditional Chinese medicine [6] - The company aims to achieve a control rate of 70% for key processes in the TCM industry by 2030, focusing on smart manufacturing and big data analysis [6] - The company demonstrates resilience and vitality as a time-honored TCM enterprise, with expectations for enhanced core competitiveness amid the digital transformation wave [7]

4月29日下午，由暨南大学科技处主办，暨南大学中医学院、仲景宛西制药股份有限公司、广东省中医 药信息化重点实验室承办的"暨南大学-仲景宛西制药临床研究项目合作签约仪式暨国家自然科学基金区 域联合集成项目临床方案论证会"在暨南大学管理学院顺利召开。 原暨南大学党委常委、副校长张荣华教授，暨南大学中医学院院长朱晓峰教授，暨南大学附属第一医院 骨关节科副主任兼中心实验室主任张还添教授，广州中医药大学第二附属医院(广东省中医院)脑病中心 研究员孙景波教授，仲景宛西制药股份有限公司副总经理马云，以及深圳、东莞、佛山、中山等广东多 地医学专家学者出席并参与项目的方案研讨。 张荣华教授代表暨南大学发表致辞并签约。作为课题总负责人，张教授对国家自然科学基金区域联合集 成项目"老年退行性疾病肾虚证本质及中医药调控机制的多元学科集成研究"进行了详细介绍。 当前，我国老龄化进程加速，老年退行性疾病如骨质疏松、膝骨关节炎、阿尔茨海默病等发病率逐年攀 升，给社会、家庭和个人带来了沉重的负担。中医药则从整体调节入手，尤其在"肾虚证"的防治方面具 有独特优势，开展老年骨质疏松症肾虚证、膝骨关节炎肾虚证、阿尔茨海默病肾虚证的临床研究，探索 ...

4月29日，由暨南大学科技处主办，暨南大学中医学院、仲景宛西制药股份有限公司、广东省中医药信 息化重点实验室承办的"暨南大学-仲景宛西制药临床研究项目合作签约仪式暨国家自然科学基金区域联 合集成项目临床方案论证会"在广州召开。 暨南大学原党委常委、副校长张荣华教授，暨南大学中医学院院长朱晓峰教授，暨南大学附属第一医院 骨关节科副主任兼中心实验室主任张还添教授，广州中医药大学第二附属医院(广东省中医院)脑病中心 研究员孙景波教授，仲景宛西制药股份有限公司副总经理马云，以及深圳、东莞、佛山、中山等广东多 地医学专家学者出席并参与项目的方案研讨。 活动现场，张荣华与马云分别代表双方进行了签约。作为课题总负责人，张荣华教授对国家自然科学基 金区域联合集成项目"老年退行性疾病肾虚证本质及中医药调控机制的多元学科集成研究"进行了详细介 绍。 张荣华表示，该项目基于"肾主骨、生髓、通于脑"中医理论，针对中医优势病种老年退行性疾病，如老 年性骨质疏松症、膝骨关节炎、阿尔茨海默病等的病理机制、关键靶点、药物选择及早期干预等关键问 题开展多学科交叉研究，旨在阐明肾虚在疾病形成、演变中的规律，努力实现老年退行性疾病中医药防 治的创 ...